Non-Alcoholic Steatohepatitis (NASH) Market

Non-Alcoholic Steatohepatitis (NASH) Market Size, Share & Trends Analysis Report

Non-Alcoholic Steatohepatitis (NASH) Market Size, Share & Trends Analysis Report By Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc, Others) Based On Region, And Segment Forecasts, 2022 - 2028

Report ID : BMRC 1852
Number of pages : 300
Published Date : Nov 2022
Category : Healthcare
Delivery Timeline : 48 hrs

Global Non-alcoholic steatohepatitis (NASH) Market Size, Trends, Competitive, Historical & Forecast Analysis to 2022-2028.

Scope of Non-alcoholic Steatohepatitis Market:

Non-alcoholic steatohepatitis (NASH) is a type of liver disease in which fat builds up in the liver of people who drink little or no alcohol. This causes inflammation of the liver and damage to the cells in the liver; it is a part of a group of conditions called NAFLD (non-alcoholic fatty liver disease).  Non-alcoholic steatohepatitis (NASH) can get worse and cause scarring of the liver, which leads to cirrhosis and liver failure. People with nonalcoholic steatohepatitis are at an increased risk of spreading liver cancer. It is more common in middle-aged adults, especially in those who are overweight or obese or who have diabetes or high levels of cholesterol and triglycerides (a type of fat) in the blood.

Furthermore, obesity, high cholesterol, high triglycerides, metabolic syndrome, insulin resistance, and type 2 diabetes are some causes that helps to foster the growth of the non-alcoholic steatohepatitis (NASH) market. Nonalcoholic steatohepatitis (NASH) is a clinicopathological syndrome caused by genetic, environmental, and metabolic stress-related factors and clinically manifested as fat accumulation in hepatocytes. Specifically, this accumulation exceeds 5% of hepatic wet weight or changes in the fatty content took place in over 1/3 of hepatocytes per unit area even though the overconsumption of alcohol can be expressly excluded.

In the changing modern times, the mindset of the people is also changing, and this is also changing the preferences of the people such as eating processed food which leads to various health conditions like obesity, fatty liver and others. Many new diseases are arising due to various reasons like, liver disease, obesity, high cholesterol, high triglycerides, metabolic syndrome, insulin resistance, and type 2 diabetes are some diseases that may increase the risk of developing non-alcoholic steatohepatitis (NASH).  Such as, estimated that there were 18.2 million people in the U.S. living with T2DM and NAFLD, of which 6.4 million had NASH. Twenty-year costs for NAFLD in these patients were $55.8 billion. Over the next 20 years, NASH with T2DM will account for 65,000 transplants, 1.37 million cardiovascular-related deaths, and 812,000 liver-related deaths.

The rising presence of non-alcoholic Steatohepatitis (NASH) along with the growing requirement for effective diagnostic tools is also driving the growth of the global non-alcoholic Steatohepatitis biomarkers market. Many pharmaceutical and research industries are working on the development of new drugs and treatments for NASH, and the number of research stations is increasing day by day due to funding provided by the government and non-government organizations. Industry participants are more looking into the availability of cost-effective solutions for NASH and thereby increasing R&D activities for the development of novel drug delivery and technologies. However, a lack of awareness and a greater number of people with undiagnosed disease conditions are anticipated to restrict the market growth of the non-alcoholic steatohepatitis biomarkers market. Moreover, in spite of that, the significant increase in the development of novel biomarkers is expected to generate huge opportunities for the further growth of the global non-alcoholic steatohepatitis market.

Segmentation Analysis of Non-alcoholic steatohepatitis Market

By Disease cause 

  • Hypertension
  • Heart Disease
  • High blood Lipid
  • Type 2 diabetes
  • Obesity

By Drug Type

  • Vitamin E & Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cencicriviroc
  • Others

Non-alcoholic Steatohepatitis (NASH) Companies

  • Allergan plc. (Tobira Therapeutics)
  • Cadila Healthcare Limited
  • Conatus Pharmaceuticals Inc.
  • Galmed Pharmaceuticals Ltd
  • Gemphire Therapeutics Inc.
  • Genfit SA
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Novartis International AG
  • Shire Plc.

NASH Market Reginal Analysis:

North America is expected to witness significant growth in the global non-alcoholic steatohepatitis market due to the increasing prevalence of non-alcoholic fatty liver disease in this region. Non-alcoholic fatty liver disease (steatohepatitis) is considered the most common form of chronic liver disease. As per Science Daily, 47% of the adult population in the United States may suffer from obesity by 2030, as compared to 37.7% in 2014. This represents an estimated 25% increase in obesity, by 2030.  According to Science Daily, on the economic impact of the disease. The rising number of overweight patients in this region is also supplementing the growth of the non-alcoholic steatohepatitis market. In this region, the non-alcoholic fatty liver disease (NAFLD) affects about 100 million every year, and the cost of the disease impacting the U.S. healthcare system is nearly 32 USD billion annually. Europe is expected to witness a positive growth in the global non-alcoholic steatohepatitis market owing to the increasing cases of non-alcoholic steatohepatitis in this region.

Market Trends Analysis of Non-Alcoholic Steatohepatitis Market:

There is no major trend available in the market as there is no approved treatment for NAFLD/NASH at global level and this could also limit physician motivation to put patients through the burden of a diagnosis. Thus, due to the lack of treatment options, standard of care involves only lifestyle interventions such as weight loss, exercise, diet, abstinence from alcohol to address the close relationship between NAFLD/NASH and metabolic syndrome. With the exciting recent developments in NAFLD/NASH clinical trials many companies have started to develop new drugs in which with multiple drugs currently in Phase III trials and many more in the global pipeline.

But there are some alternative options available in the market such as the following:

  • Liver Transplantation: NASH cirrhosis and hepatocellular carcinoma caused by NASH will soon become a major indication for liver transplantation as Non-alcoholic steatohepatitis (NASH) and any associated fibrosis, consult a greater risk of liver-related morbidity & mortality amongst patients with NAFLD. Thus, Liver transplantation is the only treatment for advanced cirrhosis with liver failure and transplantation is increasingly performed in people with NASH. For instance; According to research group at the 67th Meeting of the American Association for the Study of Liver Diseases in 2016, the prevalence rate of NASH & NAFLD is growing in the United States due to obesity & it is especially high among people with severe obesity. Researchers found that NASH was the fastest-growing cause of hepatocellular carcinoma (HCC) in the United States between 2002 & 2016. So, by using the Scientific Registry of Transplant Recipients, the researchers compared liver transplant waiting lists between 2002 and 2019. In which a total of about 168,441 people with chronic liver disease were listed for a transplant between 2002 and 2019, including about 16.5% with HCC. In 2019 hepatitis C remained the leading indication for liver transplant wait listing i.e. about 40% overall but in several sub-groups NASH had become the most common reason. Thus, in trend analysis, NASH was the most rapidly increasing suggestion for liver transplantation in patients without HCC (Kendall tau=0.97; P<.001) and in patients with HCC (tau=0.94; P<.0001).
  • Liver Biopsy: Assessment of patients with nonalcoholic steatohepatitis (NASH) suggests the need of appropriate assessment of disease severity i.e. the presence of NASH as well as of the disease stage i.e. the extent of liver fibrosis. Liver biopsy (LB) is still considered the gold standard for diagnosing NASH as well as for establishing the degree of liver fibrosis. Liver biopsy and histopathologic examination are important components of the diagnostic evaluation in patients with suspected alcoholic liver disease (ALD). They are the most sensitive and specific means of evaluating the degree of liver cell injury and hepatic fibrosis.
  • Dietary Changes and Physical Activity in NASH: It is known that high-fat, high-sugar, hypercaloric diets increase the risk of hepatic steatosis. Thus, by achieving weight loss by caloric restriction reduces hepatic inflammation and fibrosis and reduces nonalcoholic steatohepatitis. A calorie-restricted diet is the most important factor in nutritional interventions in NASH. For example; according to the recent European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) Clinical Practice Guidelines, the Mediterranean diet was recommended for NAFLD patients as this Mediterranean diet minimizes consumption of processed, high-sugar food and high-fructose food. Fructose has been shown to increase hepatic TNF production, lipid peroxidation and might promote hepatic steatosis and NAFLD. Additionally, NAFL and NASH patients tend to consume a lower amount of omega-3 PUFA versus a control group of patients. Another lifestyle modification important for the treatment of NAFLD that is closely related to weight loss is physical activity and exercise. It was shown that exercise significantly reduces steatosis and lowers the risk of NAFLD patients progressing to NASH
Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2028
Market Size in 2021: USD XXX Million 
Base year considered 2020
Forecast Period CAGR %:


Market Size Expected in 2028: USD XXX Million 
Tables, Charts & Figures: 175
Pages 200
NASH Companies Allergan plc. (Tobira Therapeutics), Cadila Healthcare Limited, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd, Gemphire Therapeutics Inc., Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novartis International AG, Shire Plc.
Segments Covered By Disease cause, By Drug Type
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits of Global Non-alcoholic steatohepatitis Market Report:

  • Global Non-alcoholic steatohepatitis market report covers in-depth historical and forecast analysis.
  • Global Non-alcoholic steatohepatitis market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
  • Global Non-alcoholic steatohepatitis market report helps to identify opportunities in the marketplace.
  • Global Non-alcoholic steatohepatitis market report covers an extensive analysis of emerging trends and competitive landscape.

On Special Requirement Non-alcoholic steatohepatitis Market Report is also available for below Regions and Country:

North America

  • U.S.
  • Canada


  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe


  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA